SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (3758)10/10/1999 12:37:00 PM
From: quidditch  Read Replies (1) of 10280
 
V1, rkrw, Peter, Rick: perhaps I'm being unduly naive, here, but it's difficult for me to believe that SEPR would pursue this potentially high impact Phase III on the effect of the S-isomer if it did not have some fairly substantial basis to conclude that the results of the trial would yield statistically material evidentce that racemic albuterol adversely affects base-line lung function as compared to the single isomer form of levalbuterol. Would management put this on the line like this to savage nascent xopenex?

Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News